Phase 2 N=131 Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
Neurotrophic Keratitis
Primary: Efficacy as Assessed by Complete Corneal Healing — 21; 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=37 Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
Neurotrophic Keratitis
Primary: Corneal Epithelial Healing — 5; 28 Participants
Phase 2 N=174 Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
Neurotrophic Keratitis · Keratitis · Corneal Ulcer
Primary: Percentage of Patients Achieving Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer — 55; 58; 20; 45 percentage of subjects — p=<0.001
Phase 2 N=113 Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
Neurotrophic Keratopathy
Primary: Mean Change From Baseline in Corneal Fluorescein Staining — -0.6; -0.9 score on a scale
Phase 2 N=48 Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
Neurotrophic Keratitis
Primary: Complete Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer Defined by Central Reviewer — 70; 29; 30; 71 percentage of participants — p==0.006
Phase 2 N=108 REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
Neurotrophic Keratitis
Primary: Corneal Healing — 4; 2; 1; 2 Participants
N/A N=24 DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Neurotrophic Keratitis
Primary: Number/Percentage of Patients Who Achieved Corneal Epithelial Healing at NGF0120 Week 8 (EoT NGF0120=Baseline NGF0122) and Remained Healed at Month 24 and Month 30 of…
Phase 3 N=152 Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
Keratitis · Corneal Ulcer
Primary: Number of Participants With a Reduction in Neurotrophic the Keratitis/Ulcer Area on Day28 — 37; 44 Participants
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
N/A N=44 Corneal Nerves Function and Structure
Diabetic Peripheral Neuropathy
Primary: Cornea Sensitivity — 0.177; 0.293 time ratio of eyelids closed vs. open — p=<0.001
Phase 2 N=20 Treatment of Corneal Neovascularization With Topical Pazopanib
Corneal Neovascularization
Primary: Heart Rate — 68.7 Beats per Minutes
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
N/A N=12 Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Atopic Keratoconjunctivitis
Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002
N/A N=40 Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy
Corneal Wound Healing
Primary: Number of Days to Complete Re-epithelialization — 4.6; 4.1 days to complete re-epithelialization
Phase 2 N=1 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Chemical Injuries · Unspecified Complication of Corneal Transplant · Autoimmune Diseases
Primary: Changes in Corneal Thickness at 1 Millimeter — 730; 760; 700; 720 micrometer
Phase 2 N=102 Exploratory Study of OPC-12759 Ophthalmic Suspension
Keratoconjunctival Epithelial Disorder
Primary: Change in the Keratoconjunctival Staining Score From Baseline — -3.4; -3.1 scores on a scale — p=0.576
Phase 3 N=745 Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Tear Production — 16.6; 9.2 Percentage of eyes
N/A N=5 Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
Corneal Ulcer · Leukoma
Primary: Incidence of Treatment-Emergent Adverse Events — 0 events
Phase 1 N=165 Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Corneal Epithelial Defect · Diabetic Retinopathy · Penetrating Keratoplasty
Primary: Patients With Corneal Epithelial Healing Time Within 14 Days — 78; 73 participants
N/A N=55 TrueTear in Sjogren's Disease Patients
Dry Eye Syndromes · Sjogren's Syndrome
Primary: Schirmer Testing — 10.2; 0.8; 13.5 mm.
N/A N=26 Keratometric Tear Breakup Time and Fluorescein Tear Breakup Time
Dry Eye
Primary: Difference Between Keratometric Tear Break Up Time (KTBUT) and Fluorescein Tear Break Up Time (FTBUT) — 5.95; 5.39 time in seconds — p=0.074
Phase 2 N=117 Traumatic Optic Neuropathy Treatment Trial (TONTT)
Traumatic Optic Neuropathy
Primary: Number of Participants With Change/Improvement Visual Acuity From the Beseline — 28; 3; 5 Participants
Phase 2 N=180 A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
Ocular Discomfort
Primary: Change From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment. — -37.2; -35.7; -37.8; -37.3 score on a scale — p==0.974
Phase 2 N=150 An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Scores — -38.8; -34.0; -32.2; -31.07 units on a scale — p==0.428
N/A N=37 Endothelial Bleb Response With Toric Lenses
Ametropia
Primary: Endothelial Bleb Areas on Cornea: Session A- Open Eye — 0.1; 2.0; 0.2; 2.1 Percent Difference of Bleb Area
Phase 1 N=24 Topical Avastin for Treatment of Corneal Neovascularization
Corneal Neovascularization
Primary: The Size and Extent of Corneal Neovascularization Will be Measured by Computerized Image Analysis of Corneal Photographs Taken Throughout the Study. — 27.9 percent…
Phase 1 N=60 Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
Glaucoma
Primary: Incidence of Events as of Primary Safety Outcomes — 0; 2; 0; 0 Number of events
N/A N=18 Corneal Topographer Fluorescein Patterns
Keratoconus
Primary: Number of Participants With an Observable Difference Between Virtual Versus Actual Fluorescein Patterns — 0 participants
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
Phase 2 N=11 OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
Geographic Atrophy · Age-Related Macular Degeneration · AMD
Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters